NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company") today closed its recently announced public offering of 1,945,000 common shares in the capital of the Company (the "Common Shares") at a price of US$90.00 per Common Share for gross proceeds of US$175,050,000 (the "Offering"). In connection with the Offering, the Company has granted the underwriters a 30-day option to purchase up to an additional 291,750 Common Shares at the public offering price, less underwriting discounts and commissions. All of the securities sold in this Offering were offered by Bright Minds.

The Company intends to use the net proceeds from the Offering to fund future clinical trials for the Company's drug candidates, including for absence seizures, DEE, and Prader-Willi Syndrome, as well as initiation of phase 1 clinical drug trials for BMB-105, and additional research and development work on earlier phase programs, as well as for general corporate and working capital purposes.

Jefferies, TD Cowen, Piper Sandler & Co., and Cantor acted as joint book-running managers for the Offering.

The Company has filed a shelf registration statement on Form F-3 (the "Registration Statement") with the U.S. Securities and Exchange Commission ("SEC") which was declared effective by the SEC on September 2, 2025. The Offering was made solely by means of a prospectus and a prospectus supplement that form a part of the Registration Statement. Copies of the final prospectus supplement and accompanying prospectus relating to the Offering may be obtained for free by visiting EDGAR on the SEC website at www.sec.gov, or from (i) Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, by telephone at (877) 821-7388 or by email (ii) TD ...